应用利培酮与氯氮平治疗精神分裂症的临床有效性对照分析

Comparative Analysis of Clinical Efficacy of Risperidone and Clozapine in the Treatment of Schizophrenia

目的探讨应用利培酮与氯氮平治疗精神分裂症的临床有效性对照。方法选择该院100例2017年1月—2018年11月精神分裂症患者。随机分组,氯氮平组采取氯氮平治疗,药物联合治疗组则采取氯氮平+利培酮治疗。比较两组精神分裂症疗效;精神分裂症好转的时间、住院的时间;治疗前后患者简明健康量表SF-36量表测评值、阴性和阳性症状积分、BPRS分值;不良反应发生率。结果药物联合治疗组总有效率100%高于氯氮平组72%,差异有统计学意义(χ^2=6.923,P<0.05)。治疗前氯氮平组、药物联合治疗组简明健康量表SF-36量表测评值、阴性和阳性症状积分、BPRS分值比较(P>0.05);治疗后药物联合治疗组简明健康量表SF-36量表测评值、阴性和阳性症状积分、BPRS分值变化幅度更大,差异有统计学意义(P<0.05)。药物联合治疗组治疗结束后精神分裂症好转的时间、住院的时间分别是(6.11±1.41)d、(9.13±2.21)d,与氯氮平组比较有优势,差异有统计学意义(t=6.824、7.523,P<0.05),药物联合治疗组和氯氮平组不良反应发生率相似(χ^2=0.000,P>0.05)。结论氯氮平+利培酮治疗精神分裂症效果好,可有效改善患者的症状,改善患者的生活质量,缩短住院的时间,且不良反应少,安全性高。

Objective To investigate the clinical efficacy of risperidone and clozapine in the treatment of schizophrenia. Methods 100 patients with schizophrenia from January 2017 to November 2018 were enrolled in this hospital. Randomly, the clozapine group was treated with clozapine and the drug combination group was treated with clozapine + risperidone. The efficacy of schizophrenia was compared between the two groups;the time of schizophrenia improvement, the time of hospitalization;the SF-36 scale evaluation value, the negative and positive symptom scores, and the BPRS score of the patient's concise health scale before and after treatment;the incidence of adverse reactions. Results The total effective rate was 100% higher in the drug combination group than 72% in the clozapine group,the difference was statistically significant(χ^2= 6.923, P<0.05). Preoperative clozapine group, drug combination treatment group, SF-36 scale, negative and positive symptom scores, BPRS scores(P>0.05);post-treatment drug combination treatment group concise health scale SF- The scores of 36 gauges, negative and positive symptom scores, and BPRS scores were larger,the difference was statistically significant(P<0.05). The time and hospitalization time of schizophrenia after treatment in the drug combination treatment group were(6.11±1.41)d and (9.13±2.21)d, respectively. Compared with the clozapine group,the difference was statistically significant(t=6.824, 7.523, P<0.05). The incidence of adverse reactions was similar in the combination therapy group and the clozapine group(χ^2=0.000, P>0.05). Conclusion Clozapine + risperidone is effective in the treatment of schizophrenia, which can effectively improve the symptoms of patients, improve the quality of life of patients, shorten the length of hospitalization, and have fewer adverse reactions and high safety.